FDA schedules advisory committee meeting for Geron's imetelstat NDA on March 14, 2024

GERON CORP

FDA's Oncologic Drugs Advisory Committee will review imetelstat for transfusion-dependent anemia in lower-risk MDS on March 14, 2024.
Meeting is scheduled from 9:30 a.m. to 3:00 p.m. ET, and will be open to the public.
PDUFA action date for the NDA remains June 16, 2024.
Federal Register notice published January 30, 2024 provides details of the advisory committee meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.